Posts (26)
- Construction of a New Industrial Facility in Gannat
- Laboratoire Unither Coutances inaugurates its new premises and production facilities
- Official launch of the CURECALL solution to ophthalmologists in France!
- UNITHER invests 68 million euros in the innovative project: Euroject®
- BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage
- Nanjing’s R&D cell inauguration
- Laboratoire Kôl Olisens® eye drops, manufactured by Unither Pharmaceuticals
- Foundation stone laid for Laboratoire Unither Amiens new building
- Unither Pharmaceuticals has completed the purchase of the Novartis site located at Butantã, in São Paulo, Brazil.
- Successful completion of the sale of the Carragelose business
- Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
- Press Release – Acquisition of the Carragelose Portfolio by Unither Pharmaceuticals
- New in corneal transplant rejection: the ANSM issues an authorisation for the first industrial eye drop based on ciclosporin 2%.
- Acquisition in China
- A BUSINESS DEVELOPER’S MISSION AT UNITHER – TO PROVIDE CUSTOMER SATISFACTION
- Advancing ophthalmology: Unither invests in its French R&D site.
- Development of a new prophylactic vaccine
- Rare Disease Day
- Manufacturing of registration batches of PXT3003 in single unit doses
- Mouthwash stick-packs
- Using Differentiated Drug-Delivery Technologies to Deliver Competitive Advantages
- Partnership with SeaBeLife to develop and produce ophthalmic drug candidate
- Why China is becoming strategic for Ophthalmology and CDMOs
- Liquid Delivery Systems for ENT Applications
- Launch of our first commercial batches of PFMD
- The Management led by Eric Goupil gathers a consortium to acquire Unither Pharmaceuticals from Ardian
Pages (63)
- Resultados
- About Us
- Agenda
- Analytical Development
- Blow-Fill-Seal (BFS)
- Breakthrough Solutions
- By technology
- By therapeutic area
- Cap 2030: our CSR strategy
- Careers
- Carragelose – Viral Infection
- Clinical Batch & Placebo Manufacturing
- Co-Development Program
- Code of Conduct
- Commercial batches manufacturing
- Configurator
- Contact
- Development
- ENT
- Euroject® – BFS Injectable
- Executive Committee
- Formulation Development
- History
- Home
- In Brazil
- In China
- In France
- In the United States
- Injectable
- Inspire Hub
- Launched Carragelose® products
- Legal Notice
- Manufacturing
- Medical devices
- Medicines
- Multi-Dose
- News
- Ophthalmic Development
- Ophthalmology
- Other Therapeutic Areas
- Out-licensing
- Overview
- Press Area
- Privacy Policy
- Procurement Policy
- Product List
- Product notices
- Rare Diseases
- Regulatory Support
- Respiratory
- Responsible Purchasing
- Results
- Small-batch commercial manufacturing – rare diseases
- Small-batch manufacturing for veterinary pharmaceuticals
- Sol-Gel™ – Ophthalmology
- Solids & Semi-Solids
- Spray
- Stability Studies
- Stick-Pack
- Technology Transfer & Pharmaceutical Scale-Up
- Uniflash® – Oro-mucosal
- Vials
- Vision and Innovation
Agenda (51)
- AAO
- AAPS
- ABRADILAN
- APAO 2026
- ARVO
- ASCRS
- BIO-Europe 2024
- BioAsia
- BioEurope Spring
- BioFIT
- Biologic Manufacturing Asia
- Biologics World Nordics
- Bionnale
- CBME China
- China Beauty Expo
- Congrès France Bioproduction
- Connect in Pharma
- Cosmofarma
- CPhI China
- CPhI Europe
- CPhI North America
- CRS 2024
- DCAT Week – Atlanta
- DCAT Week – New York
- ESCRS
- Europharm SMC
- Europharm SMC
- EuroPLX 84
- euroPLX 85 Dublin
- EuroPLX 87 Vienna
- euroPLX 90
- FCE PHARMA 2024
- Festival of Biologics 2026
- Infarma
- Insights in Ophthalmology
- INTERPHEX
- Medical Technology UK
- Octane
- OIS seco
- OIS seco
- OIS seco
- Orphan drug congress
- Pharmaceutical Manufacturing & Packaging Congress PHARMAP
- Pharmasynergy
- PharmaSynergy OTC
- Pharmasynergy-RX
- Pharmavenue
- World Vaccine Congress
- World Vaccine Congress
- World Vaccine Congress 2025
- World Vaccine Congress 2026